Purdue Pharma L.P.

• Who We Are
  • Our Culture and Values
  • Our Leadership Team
    • John H. Stewart
    • Stuart D. Baker
    • Edward B. Mahony
    • Jim Dolan
    • David Long
    • Gary L. Stiles, MD
    • Russ Gasdia
    • Craig Landau, MD
    • David Lundie
    • William Mallin
    • Philip C. Strassburger
    • Bert Weinstein
  • Partnering With Purdue
    • Licensing Proposal Form
  • Locations & Operations
    • Headquarters
    • Research Labs
    • Manufacturing
  • Compliance & Ethics
  • Purdue in the Community
    • Helping the Community
    • Helping the Environment

Partnering With Purdue

Purdue’s Licensing and Business Development executives: from left, Allen Downs, Ann Kraft, and Jim Dolan

The Benefits of a Pharmaceutical Partnership With Purdue Pharma L.P.

In today’s competitive marketplace, alliances allow companies to combine resources and expertise to advance pharma industry research and bring new medications and innovative products to market. By building strong alliances with high-quality, research-driven organizations, we provide new and improved treatments for diseases and their symptoms, and deliver the best possible care for patients.

Fully Integrated Pharmaceutical Operations

Purdue provides partner companies with extensive expertise in discovery, clinical development, project management, regulatory affairs, manufacturing, marketing, and sales. A dedicated Alliance Management function ensures that every dimension and detail involved in our collaborations gets the attention required. Purdue has regulatory expertise and experience in gaining approval from the U.S. Food and Drug Administration (FDA). Our national U.S. sales and marketing organization has the critical mass and know-how to commercialize new products quickly and effectively.

Global Reach

Purdue Pharma and its independent associated companies (including the Mundipharma/Napp companies) have a presence in more than 30 countries and a staff of more than 5,000.  Each of these international companies is a leader within their respective market for key therapeutic areas.

Expertise in Pain Management

Purdue has long-standing expertise in pain management and has transformed clinical practice to better serve the needs of patients with pain. We have conducted extensive pharma industry research into the development of analgesics that provide safe and effective pain relief to patients. We work extensively with physicians, opinion leaders, and patient advocacy groups to ensure that pain is appropriately recognized and treated.

Purdue and Shionogi & Co., Ltd., one of Japan’s largest research-based pharmaceutical companies, are collaborating on the discovery and development of new, non-opioid pain medications to treat pain. The research, which targets cellular receptors known to modulate pain responses, is being conducted jointly at Purdue’s research center in Cranbury, New Jersey, and Shionogi’s laboratories in Osaka, Japan.

Purdue has an exclusive U.S. licensing and co-promotion agreement with Labopharm Inc. of Laval, Canada for Ryzolt^® (tramadol HCl extended-release tablets), an extended release formulation of tramadol.

Expanding into Related Therapeutic Areas

Purdue has an exclusive license and collaboration agreement with Transcept Pharmaceuticals, Inc. to commercialize Intermezzo^® (zolpidem tartrate sublingual tablet).

Purdue’s Therapeutic Areas of Interest

Purdue’s licensing strategy seeks to identify late-stage products within the following therapeutic areas:

• Pain management – both non-opioids and opioids
• Sleep disorders
• Gastrointestinal disorders

Top of page